Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board
Pasithea Therapeutics Corp. (NASDAQ: KTTA) has appointed Dr. Rebecca Brown to its Scientific Advisory Board. Dr. Brown, the Director of the Neurofibromatosis Clinic at The Mount Sinai Hospital, brings extensive expertise in Neurofibromatosis type 1 (NF1) research and treatment. This appointment aligns with Pasithea's development of PAS-004, a next-generation macrocyclic MEK inhibitor for NF1 treatment.
Dr. Brown's experience, particularly in cutaneous and plexiform neurofibromas, will contribute to Pasithea's upcoming Phase 1/2a clinical trial for NF1. She highlighted PAS-004's potential advantages, including a long half-life, superior therapeutic index, cleaner safety profile, and once-daily dosing, which could represent a significant advancement in NF1 treatment.
Pasithea Therapeutics Corp. (NASDAQ: KTTA) ha nominato Dr.ssa Rebecca Brown nel suo Comitato Consultivo Scientifico. La Dr.ssa Brown, Direttore della Clinica per la Neurofibromatosi presso il Mount Sinai Hospital, porta con sé una vasta esperienza nella ricerca e nel trattamento della neurofibromatosi di tipo 1 (NF1). Questa nomina è in linea con lo sviluppo di Pasithea del PAS-004, un inibitore MEK macrocilico di nuova generazione per il trattamento della NF1.
La esperienza della Dr.ssa Brown, in particolare nelle neurofibromi cutanei e plexiformi, contribuirà al prossimo studio clinico di Fase 1/2a di Pasithea per la NF1. Ha evidenziato i potenziali vantaggi di PAS-004, tra cui una lunga emivita, un indice terapeutico superiore, un profilo di sicurezza più pulito e una somministrazione una volta al giorno, che potrebbero rappresentare un notevole progresso nel trattamento della NF1.
Pasithea Therapeutics Corp. (NASDAQ: KTTA) ha nombrado a Dr. Rebecca Brown en su Junta Asesora Científica. La Dra. Brown, Directora de la Clínica de Neurofibromatosis en el Hospital Mount Sinai, aporta una amplia experiencia en la investigación y tratamiento de la neurofibromatosis tipo 1 (NF1). Este nombramiento se alinea con el desarrollo de Pasithea del PAS-004, un inhibidor MEK macrocíclico de nueva generación para el tratamiento de NF1.
La experiencia de la Dra. Brown, especialmente en neurofibromas cutáneos y plexiformes, contribuirá al próximo ensayo clínico de Fase 1/2a de Pasithea para NF1. Ella destacó las posibles ventajas de PAS-004, que incluyen una larga vida media, un índice terapéutico superior, un perfil de seguridad más limpio y una dosificación una vez al día, lo que podría representar un avance significativo en el tratamiento de NF1.
파시테아 제약 회사(Pasithea Therapeutics Corp., NASDAQ: KTTA)는 레베카 브라운 박사를 과학 자문 위원회에 임명했습니다. 브라운 박사는 마운트 시나이 병원의 신경섬유종증 클리닉 책임자로, 신경섬유종증 1형 (NF1) 연구 및 치료에 대한 폭넓은 전문 지식을 가지고 있습니다. 이 임명은 NF1 치료를 위한 차세대 매크로사이클 MEK 억제제인 PAS-004의 개발과 일치합니다.
브라운 박사의 경험, 특히 피부 및 망상 신경섬유종에 대한 지식이 NF1을 위한 파시테아의 1/2a상 임상 시험에 기여할 것입니다. 그녀는 PAS-004의 잠재적 장점을 강조했으며, 여기에는 긴 반감기, 우수한 치료 지수, 깨끗한 안전 프로필 및 하루 한 번 복용할 수 있는 점이 포함되어 있습니다. 이는 NF1 치료에 큰 발전이 될 수 있습니다.
Pasithea Therapeutics Corp. (NASDAQ: KTTA) a nommé Dr. Rebecca Brown à son Comité Consultatif Scientifique. La Dr. Brown, Directrice de la Clinique de Neurofibromatose à l'Hôpital Mount Sinai, apporte une vaste expertise en recherche et traitement de la neurofibromatose de type 1 (NF1). Cette nomination s'inscrit dans le cadre du développement par Pasithea du PAS-004, un inhibiteur MEK macrocyclique de nouvelle génération pour le traitement de la NF1.
L'expérience de la Dr. Brown, notamment en ce qui concerne les neurofibromes cutanés et plexiformes, contribuera au prochain essai clinique de Phase 1/2a de Pasithea pour la NF1. Elle a souligné les avantages potentiels de PAS-004, y compris une longue demi-vie, un indice thérapeutique supérieur, un profil de sécurité plus propre et une posologie une fois par jour, ce qui pourrait représenter une avancée majeure dans le traitement de la NF1.
Die Pasithea Therapeutics Corp. (NASDAQ: KTTA) hat Dr. Rebecca Brown in ihren Wissenschaftlichen Beirat berufen. Dr. Brown, Direktorin der Neurofibromatose-Klinik am Mount Sinai Hospital, bringt umfassende Expertise in der Forschung und Behandlung von Neurofibromatose Typ 1 (NF1) mit. Diese Ernennung steht im Einklang mit Pasitheas Entwicklung von PAS-004, einem innovativen makrozyklischen MEK-Inhibitor zur Behandlung von NF1.
Dr. Browns Erfahrung, insbesondere in Bezug auf kutane und plexiforme Neurofibrome, wird zum bevorstehenden Phase 1/2a-Klinikversuch von Pasithea für NF1 beitragen. Sie hat die potenziellen Vorteile von PAS-004 hervorgehoben, darunter eine lange Halbwertszeit, einen überlegenen therapeutischen Index, ein reineres Sicherheitsprofil und eine einmal tägliche Dosierung, was einen bedeutenden Fortschritt in der Behandlung von NF1 darstellen könnte.
- Appointment of a world-leading expert in Neurofibromatosis to the Scientific Advisory Board
- Dr. Brown's expertise aligns with Pasithea's focus on developing PAS-004 for NF1 treatment
- PAS-004 shows promising preclinical data for NF1 treatment
- PAS-004 potentially offers advantages over existing treatments, including once-daily dosing and a cleaner safety profile
- None.
Dr. Brown is a world-leading expert in Neurofibromatosis (NF) and the Director of the Neurofibromatosis clinic at The Mount Sinai Hospital, NY
MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other indications, announced today that Rebecca Brown, M.D., Ph.D. has been appointed as a member of the Company’s Scientific Advisory Board.
Dr. Brown is currently Director of the Neurofibromatosis Clinic at The Mount Sinai Hospital and Assistant Professor in the Department of Neurology (Division of Neuro-Oncology), Internal Medicine, and Neurosurgery at the institution. Dr. Brown will contribute scientific insights and valuable clinical perspectives to Pasithea's development of PAS-004.
Dr. Brown has been an investigator in dozens of NF1 research studies including basic, translational, and clinical trials, with a focus on cutaneous and plexiform neurofibromas in NF1. Her research has been published extensively in major scientific journals and regularly serves as faculty at national and international meetings.
“We are honored to have Dr. Brown, an internationally recognized NF1 expert, join our Scientific Advisory Board,” commented Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. “As we plan the initiation of our Phase 1/2a clinical trial in NF1 Dr. Brown’s extensive experience in the research and treatment of both plexiform and cutaneous neurofibromas will provide an important contribution to our PAS-004 development efforts going forward.”
Dr. Rebecca Brown stated “I look forward to assisting with the development of PAS-004, a next-generation macrocyclic MEK inhibitor with promising preclinical data for the treatment of NF1.This product addresses an unmet need and potentially distinguishes itself from other drugs within the same class. The long half-life adds to other desirable features including a potentially superior therapeutic index, a cleaner safety profile, and easier compliance via once per day dosing. There have been tremendous achievements over the past 5 years in drug development for plexiform neurofibromas associated with NF1, and I believe that PAS-004 may provide the next big leap in treatment efficacy and compliance.”
Dr. Rebecca Brown’s Biography
Dr. Rebecca Brown (M.D., Ph.D.) is a board-certified adult neuro-oncologist who specializes in Neurofibromatosis (NF) and Schwannomatosis (SWN) genetic nerve tumor predisposition syndromes. She earned her Ph.D. from The University of Texas at Austin (UT Austin) in Neuroscience studying the molecular genomics and behavioral outcomes of endocrine-disrupting pollutants on females across multiple generations. Dr. Brown completed a post-doctoral fellowship at the Center for Strategic and Innovative Technologies at UT Austin in human performance research and then earned her M.D. from UT Southwestern in 2013. She completed her intern year at East Tennessee State University in 2014 and her neurology residency at Mount Sinai Hospital in NYC in 2017. She specialized in neuro-oncology during a fellowship at Memorial Sloan Kettering Cancer Center (MSKCC) completed in 2019. She worked as an instructor at MSKCC for 18 months prior to accepting a position as Assistant Professor and Director of the all-ages NF and SWN Clinic at The Mount Sinai Health System in January 2021. Dr. Brown has experience on both sides of the bench in NF laboratory research involving the RAS-RAF-MEK-ERK (MAPK) pathway, including genome editing, cell culture, xenografts, and clinical trials. Her particular interest is in developing treatments for NF1-associated dermal tumors called cutaneous neurofibromas.
About PAS-004
PAS-004 is a small molecule allosteric inhibitor of MEK 1/2, which are dual-specificity protein kinases, in the MAPK signaling pathway. The MAPK pathway has been implicated in a variety of diseases, as it functions to drive cell proliferation, differentiation, survival, and a variety of other cellular functions that, when abnormally activated, are critical for the formation and progression of tumors, fibrosis, and other diseases. MEK inhibitors block phosphorylation (activation) of extracellular signal-regulated kinases (ERK), which can lead to cell death and inhibition of tumor growth. Existing FDA-approved MEK inhibitors are marketed for a range of diseases, including certain cancers and neurofibromatosis type 1 (NF1). We believe these MEK inhibitors suffer from certain limitations, including known toxicities. Unlike current FDA-approved MEK inhibitors, PAS-004 is macrocyclic, which we believe may lead to improved pharmacokinetic and safety (tolerability) profiles. Cyclization offers rigidity for stronger binding with drug target receptors. PAS-004 was designed to provide a longer half-life with what we believe is a better therapeutic window. Further, we believe the potency and safety profile that PAS-004 has demonstrated in preclinical studies may also lead to stronger and more durable response rates and efficacy, as well as better dosing schedules. PAS-004 has been tested in a range of mouse models of various diseases and has completed preclinical testing and animal toxicology studies. Additionally, PAS-004 has received orphan-drug designation from the FDA for the treatment of NF1, which may provide seven years of marketing exclusivity upon approval of an NDA.
About Pasithea Therapeutics Corp.
Pasithea is a clinical-stage biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders and RASopathies. With an experienced team of experts in the fields of neuroscience, translational medicine, and drug development, Pasithea is developing new molecular entities for the treatment of neurological disorders, including Neurofibromatosis type 1 (NF1), Solid Tumors, and Amyotrophic Lateral Sclerosis (ALS).
Forward Looking Statements
This press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include all statements, other than statements of historical fact, regarding the Company’s current views and assumptions with respect to future events regarding its business, as well as other statements with respect to the Company’s plans, assumptions, expectations, beliefs and objectives, the success of the Company’s current and future business strategies, product development, preclinical studies clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including factors set forth in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other filings made with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.
Pasithea Therapeutics Contact
Patrick Gaynes
Corporate Communications
pgaynes@pasithea.com
FAQ
Who is the new member of Pasithea Therapeutics' Scientific Advisory Board?
What is Pasithea Therapeutics (KTTA) developing for Neurofibromatosis type 1 treatment?
What are the potential advantages of PAS-004 for NF1 treatment?
What is the current stage of development for Pasithea Therapeutics' (KTTA) PAS-004?
